Tirzepatide for Alcohol Use Disorder

NCT06994338 · Recruiting

Last updated 2026-05-28

This clinical trial tests whether the medication tirzepatide can help reduce heavy drinking days in adults with alcohol use disorder.

Status Recruiting Currently enrolling participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 42 people Planned (estimated).

Who can join Ages 21–65 · all sexes

Timeline Started 2025-10 · est. completion 2026-08

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06994338 ↗

Description as written by the study sponsor.

The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.

Treatments tested

Tirzepatide Drug

Tirzepatide injections (2.5mg, 5.0mg)
Placebo injections Drug

Placebo injections

Main thing measured	Number of heavy drinking days
Sponsor	University of Southern California
Conditions studied	Alcohol Use Disorder, Obesity and Overweight, Alcohol
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06994338 ↗